• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 3. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 4. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 5. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Cytochalasans Cytochalasins

Cytochalasin A (CAS No. 14110-64-6): A Comprehensive Overview of Its Biochemical Significance and Recent Research Applications

Cytochalasin A, a naturally occurring macrolide compound identified by its unique chemical structure, is widely recognized for its profound influence on cellular processes. With the CAS number 14110-64-6, this compound has been extensively studied in the field of biochemistry and pharmacology due to its remarkable properties. The structure of Cytochalasin A features a complex ring system that interacts selectively with cellular components, primarily targeting actin filaments and microtubules, thereby modulating various cellular functions.

The biochemical mechanism of Cytochalasin A involves its binding to actin monomers, preventing their polymerization into filaments. This interaction is pivotal in numerous cellular processes, including cell division, motility, and phagocytosis. The compound's ability to disrupt actin dynamics has made it a valuable tool in research settings, particularly in studying cell biology and cytoskeletal organization. Its pharmacological potential has also been explored in therapeutic contexts, where it shows promise in inhibiting certain pathological conditions associated with abnormal actin polymerization.

Recent advancements in the study of Cytochalasin A have highlighted its role in cancer research. Studies have demonstrated that the compound can induce apoptosis in tumor cells by disrupting their cytoskeleton, leading to cell cycle arrest and programmed cell death. Additionally, research has revealed that Cytochalasin A exhibits anti-inflammatory properties, making it a candidate for treating inflammatory diseases. These findings underscore the compound's multifaceted applications in biomedical research and drug development.

The synthetic derivatives of Cytochalasin A have also been a focus of interest, as modifications to its structure can enhance its efficacy and reduce toxicity. Researchers have developed analogs that retain the core pharmacological activity while exhibiting improved solubility and bioavailability. Such derivatives are being tested in clinical trials for their potential use in treating neurological disorders and infectious diseases. The structural analysis of these derivatives using advanced spectroscopic techniques has provided insights into their binding interactions with biological targets, further refining their therapeutic potential.

In the realm of drug discovery, Cytochalasin A serves as a key scaffold for designing novel therapeutic agents. Its unique mechanism of action has inspired the development of small molecule inhibitors targeting various disease pathways. For instance, researchers have leveraged the structural insights from Cytochalasin A to create compounds that inhibit bacterial actin assembly, offering a new strategy against antibiotic-resistant infections. This approach highlights the compound's broader implications beyond traditional cancer therapy.

The cellular signaling pathways modulated by Cytochalasin A have been extensively studied to understand their implications in disease progression. Evidence suggests that the compound can influence signaling cascades involved in cell survival, inflammation, and angiogenesis. By disrupting actin filaments, Cytochalasin A indirectly affects downstream signaling events, providing a holistic view of its biological impact. These findings are crucial for developing targeted therapies that address multiple aspects of disease pathology.

Moreover, the application of Cytochalasin A in high-throughput screening has accelerated the discovery of novel bioactive compounds. Its ability to selectively inhibit specific cellular processes makes it an ideal candidate for identifying new drug candidates with minimal off-target effects. This methodological approach has been instrumental in uncovering compounds with therapeutic potential across various domains, including oncology and neurology.

The future directions of Cytochalasin A research are promising, with ongoing studies exploring its role in regenerative medicine and tissue engineering. Preliminary data indicate that the compound can influence stem cell differentiation by modulating cytoskeletal dynamics. Such findings open up new avenues for treating degenerative diseases and injuries by harnessing the regenerative capabilities of stem cells.

In conclusion, Cytochalasin A (CAS No. 14110-64-6) is a versatile compound with significant implications in biochemistry and pharmacology. Its unique mechanism of action on actin filaments has led to numerous breakthroughs in understanding cellular processes and developing novel therapeutic strategies. The recent research advancements highlight its potential as a lead compound for drug discovery and as a tool for studying complex biological systems.

• 39156-67-7(DIHYDROCYTOCHALASIN B)
• 14930-96-2(Cytochalasin B)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)